Pupillometric Evaluation in Patients Declared Brain Dead - a Prospective Quality Control Study
Launched by UNIVERSITY HOSPITAL, BASEL, SWITZERLAND · Feb 22, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at how well doctors can check for brain death by examining a person's pupils, which are the black circles in the center of the eyes. Usually, doctors do this assessment by looking at the pupils without any special tools. However, this study aims to see if using a device called a pupillometer, which measures pupil responses more precisely and automatically, gives more reliable results. This is important for making sure the diagnosis of brain death is accurate.
To be eligible for the study, patients need to be suspected of being brain dead and have plans for diagnostic procedures related to brain death. They must be treated in the intensive care unit at the University Hospital Basel. If a patient participates, they can expect the study to involve additional, non-invasive eye exams using the pupillometer, alongside the standard clinical assessments. This research will help improve the accuracy of brain death diagnoses, which is crucial for patient care and decision-making.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Suspected diagnosis of brain death
- • Brain death diagnostic procedures planned
- • Treated at the intensive care unit at the University Hospital Basel (USB)
About University Hospital, Basel, Switzerland
The University Hospital Basel, Switzerland, is a leading academic medical center renowned for its commitment to cutting-edge research and innovative patient care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise and state-of-the-art facilities to advance medical knowledge and therapeutic options across various disciplines. With a collaborative approach that integrates clinical practice and scientific inquiry, the University Hospital Basel fosters an environment conducive to rigorous clinical trials, ensuring the highest standards of safety and efficacy. Its strategic focus on patient-centered research aims to translate scientific discoveries into tangible health solutions, benefiting both local and global communities.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Basel, , Switzerland
Basel, Basel Stadt, Switzerland
Patients applied
Trial Officials
Raoul Sutter, Prof.
Principal Investigator
University Hospital, Basel, Switzerland
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported